Noha H. Sayed , Nevine Fathy , Mona A. Kortam , Mostafa A. Rabie , Ahmed F. Mohamed , Ahmed S. Kamel
{"title":"更正:维达列汀在3-硝基丙酸大鼠模型中通过激活GLP-1受体/PI3K/Akt/BDNF通路减轻亨廷顿氏病。","authors":"Noha H. Sayed , Nevine Fathy , Mona A. Kortam , Mostafa A. Rabie , Ahmed F. Mohamed , Ahmed S. Kamel","doi":"10.1007/s13311-022-01227-6","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"19 2","pages":"Page 686"},"PeriodicalIF":5.6000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226260/pdf/","citationCount":"0","resultStr":"{\"title\":\"Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model\",\"authors\":\"Noha H. Sayed , Nevine Fathy , Mona A. Kortam , Mostafa A. Rabie , Ahmed F. Mohamed , Ahmed S. Kamel\",\"doi\":\"10.1007/s13311-022-01227-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19159,\"journal\":{\"name\":\"Neurotherapeutics\",\"volume\":\"19 2\",\"pages\":\"Page 686\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226260/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurotherapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S187874792300082X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187874792300082X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model
期刊介绍:
Neurotherapeutics® is the journal of the American Society for Experimental Neurotherapeutics (ASENT). Each issue provides critical reviews of an important topic relating to the treatment of neurological disorders written by international authorities.
The Journal also publishes original research articles in translational neuroscience including descriptions of cutting edge therapies that cross disciplinary lines and represent important contributions to neurotherapeutics for medical practitioners and other researchers in the field.
Neurotherapeutics ® delivers a multidisciplinary perspective on the frontiers of translational neuroscience, provides perspectives on current research and practice, and covers social and ethical as well as scientific issues.